Researchers at the University of Minnesota School of Medicine determined that the common blood pressure drug, losartan, is not effective in reducing outpatients with COVID-19 with mild illnesses.
In the multicenter, randomized, double-blind clinical trial, it was administered to outpatients recently diagnosed with COVID-19. losartan or a placebo and controlled for 15 days. The results of the study, which were published in Clinical medicine, demonstrated that although losartan does not reduce the likelihood of hospitalization, the medication does not appear to worsen COVID-19 symptoms or have significant or harmful side effects in patients with mild COVID-19.
“According to our results, there is no advantage in starting losartan for outpatients recently diagnosed with COVID-19, but those who already take the medication for pre-existing health conditions he should feel safe to continue, “said Michael Puskarich, MD, an associate professor in the Department of Emergency Medicine at U of M School of Medicine and a co-researcher in that study. He is also a physician at emergencies at Hennepin Healthcare.
Contradictory hypotheses since the onset of the pandemic led this research team to investigate losartan as a potential treatment option. While some experts believed that drugs like losartan could reduce inflammation and help the recovery of infected people, others were concerned that the drug could worsen the symptoms of COVID-19.
“Given the binding of SARS-CoV-2 to ACE2, there has been significant interest in research into the usefulness of ACE and AT1R blocking agents in combating COVID-19. This study provides an idea that for to patients with mild COVID-19 who do not need hospital admission, that there is no benefit or harm from these agents, ”said co-principal investigator Christopher Tignanelli, MD, MS, assistant professor in the Department of Surgery. the U of M Medical School and critical care surgeon at M Health Fairview.
The same team has been working on another trial for hospitalized patients to assess whether losartan prevents lung injury in hospitalized patients with COVID-19 pneumonia. They have completed the registration and are currently analyzing the data.
Michael A. Puskarich et al, A multicenter phase II randomized clinical trial of losartan in symptomatic outpatients with COVID-19, Clinical Medicine (2021). DOI: 10.1016 / j.eclinm.2021.100957
University of Minnesota School of Medicine
Citation: Losartan proved ineffective in reducing hospitalization for mild COVID-19 (2021, June 18) recovered on June 19, 2021 at https://medicalxpress.com/news/2021-06-losartan-ineffective-hospitalization- mild-covid-.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.